Back to dashboard
MedicaidPrior AuthLow impact

BT2025111: IHCP provides PA criteria for newly added physician-administered drug Tecelra (Q2057)

Indiana Medicaid (IHCP)·IN · Oncology, Hematology·Pharmacy
Effective date
Apr 1, 2025
We identified it
Jun 18, 2026
Days to comply

Summary

Indiana Medicaid has established prior authorization criteria for newly covered HCPCS code Q2057 (Tecelra), a specialized cancer treatment for adults with synovial sarcoma. The drug requires strict eligibility criteria including prior chemotherapy, specific genetic markers, and tumor expression testing.

Action Required

Action needed
By next billing cycle: Billing team must update system to flag HCPCS code Q2057 for prior authorization requirements through Acentra Health (866-725-9991) before billing. Ensure all Q2057 claims include required NDC codes and use revenue code 636 for institutional outpatient claims. Submit FFS claims to Gainwell Technologies.

Affected Billing Codes

Q2057
BT2025111: IHCP provides PA criteria for newly added physician-administered drug Tecelra (Q2057) | Indiana Medicaid (IHCP) | PolicyChanges.app